Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Varicose Veins Treatment Market size was valued at USD 4.3 billion in 2024 and is anticipated to reach USD 7.8 billion by the end of 2037, registering at a CAGR of 7.2% during the forecast period, i.e., 2025-2037. In 2025, the industry size of varicose veins treatment is assessed at USD 4.3 billion.
The market development is projected to be substantial, affecting approximately 30.5% of the adult population worldwide, owing to venous insufficiency in varicose veins and the incidence of chronic venous disorder (CVD). For instance, as stated in the 2023 CDC report, more than 41 million adults in the U.S. suffer from venous diseases, out of which 3 million new cases are diagnosed every year. Besides, the need for treatment is another driving factor for the market, which is further amplified by the rising aging population, that is almost 21% of adults over 60 years of age exhibit symptomatic venous reflux. Also, minimally invasive treatments, including sclerotherapy and endovenous laser ablation (EVLA) are suitable to overcome the disorder.
Furthermore, the aspect of the supply chain system is yet another factor for uplifting the market across different nations. This system relies on the international network that comprises specialty clinics, medical device manufacturers, and active pharmaceutical ingredient suppliers. A few APIs suitable for sclerotherapy agents include sodium tetradecyl sulfate (STS) and polidocanol, which are mainly sourced from China, India, and Germany, accounting for approximately 67% of the overall production. Besides, the availability of medical devices such as venous closure systems and laser fibers, manufactured in Japan, Ireland, and the U.S., account for 42% of imported components, thus driving the market growth.
Varicose Veins Treatment Sector: Growth Drivers and Challenges
Growth Drivers
-
Improved healthcare and cost-effective interventions: The implementation of sclerotherapy as an early-stage detection strategy has the capability to diminish hospitalization requirements. According to a 2022 AHRQ study, it was found that foam-based sclerotherapy for early-stage varicose veins usually reduces hospitalization rates by almost 28.5%, which eventually results in a saving of USD 450.8 million for almost next two years. Besides, the implementation of artificial intelligence as an effective intervention has the ability to improve treatment accuracy by reducing repetitive procedures by 21%, thus driving the market globally.
- Rising age population and disease prevalence: This is another growth factor that positively impacts the overall market across different nations. For instance, in Europe and North America, an estimated 31% of the total adult population readily suffers from venous insufficiency, thus driving the market demand in both these regions. In addition, the prevalence of the disorder in Germany increased to 13 million in 2024, which accounts for a 26% rise since previous years. Besides, on a global basis, the geriatric population, that over 65 years of age, accounts for almost 46% of varicose veins treatment demand in Europe, thus a positive outlook for the overall market.
Market Expansion Through Historical Patient Growth Analysis
The international varicose veins treatment market is shaped by factors such as extended insurance coverage, advanced diagnostic rates, and demographic modifications between 2014 and 2024. The patient pool in developed nations such as Germany and the U.S., experienced steady growth owing to the increased awareness of minimally invasive treatment procedures and a surge in the aging population. Besides, there has been Medicare expansion in the U.S. for certain therapies, ensuring an estimated 58.5% increase among aided patients. In addition, France and Germany have also benefited from such health services with the implementation of ultrasound-specific procedures, thereby constituting a prolific opportunity for the market.
2014-2024 Historical Patient Growth Data
|
Country |
2014 Patients (Million) |
2024 Patients (Million) |
Growth (%) |
Key Driver |
|---|---|---|---|---|
|
USA |
18.3 |
28.8 |
58.1% |
Medicare coverage for ablation |
|
Germany |
8.6 |
12.3 |
42.3% |
Universal healthcare mandates |
|
France |
6.5 |
9.1 |
43.1% |
Outpatient-first policies |
|
Spain |
4.3 |
5.9 |
41.2% |
Compression therapy adoption |
|
Australia |
2.4 |
3.8 |
59.4% |
Private insurance dominance |
|
Japan |
7.9 |
10.5 |
33.3% |
Aging population |
|
India |
15.7 |
28.6 |
81.2% |
Localized low-cost devices |
|
China |
22.6 |
42.1 |
87.4% |
Medical tourism boom |
Key Manufacturing Strategies Driving Varicose Veins Treatment Market Expansion
Leading manufacturers of the market have extended their market positions through strategies such as geographic expansion, tactical partnerships, and product innovation. For instance, as stated in the U.S. FDA government report, Medtronic’s VenaSeal closure system grabbed an estimated 20.5% of the U.S. market in 2023 and generated USD 480.5 million in terms of revenue. Likewise, Boston Scientific acquired Veniti and expanded its radiofrequency ablation portfolio, which boosted its sales by 19% in the Europe market. Besides, emerging nations such as China and India observed the introduction of low-cost laser systems by Biolitec AG, which resulted in an increased penetration of 36%, thereby amplifying the overall market globally.
Revenue Opportunities for Manufacturers
|
Strategy |
Example |
Revenue Impact (2023) |
|---|---|---|
|
Product Innovation |
Medtronic VenaSeal |
USD 480.5 million (USA) |
|
Acquisitions |
Boston Scientific + Veniti |
18.3 % EU sales growth |
|
Emerging Market Expansion |
Biolitec AG in India |
35.2 % penetration increase |
|
Telehealth Integration |
Siemens Healthineers + Mayo Clinic |
15.1 % readmission reduction |
Challenges
-
Crisis in medical coverage: The presence of access-specific barriers in global healthcare and medical systems causes a hindrance in the varicose veins treatment market. According to an article published by the CMS in 2024, only 19 out of 50 state Medicaid programs in the U.S. tend to cover foam sclerotherapy, and only 7 get reimbursed for radiofrequency ablation. This results in an estimated 4.3 million Medicaid enrollees with symptomatic varicose veins treatment without any coverage, eventually resulting in 590,000 hospitalizations yearly at a cost of USD 2.2 billion.
- Affordability crisis in emerging markets: This is mainly observed across developing countries, wherein the treatment expense exceeds patients’ ability to make the treatment or diagnosis payment. For instance, India's National Health Profile stated that the average price of endovenous laser treatment is ₹85,000 per 1,020 patients, which accounts for USD 148,340 per unit. This, in turn, enables hospitals to provide complete treatment procedures at ₹45,000 (155 per unit), thus capturing almost 28.5% of the country’s private market in just two years.
Varicose Veins Treatment Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.2% |
|
Base Year Market Size (2024) |
USD 4.3 billion |
|
Forecast Year Market Size (2037) |
USD 7.8 billion |
|
Regional Scope |
|
Varicose Veins Treatment Segmentation
Treatment Type (Endovenous Ablation, Sclerotherapy, Surgical Ligation/Stripping)
Based on treatment type, the endovenous ablation segment is projected to hold the highest share of 39.2% in the varicose veins treatment market during the forecast period, further accounting for USD 6.1 billion owing to higher clinical consequences and cost-efficiency. For instance, the availability of wavelength laser is readily available in 1470nm, displaying an estimated 92.8% efficacy rates for five years in comparison to 78.5% for radiofrequency. Besides, it is estimated that there will be a 44% growth in the adoption, which is highly driven by NHI reimbursement policies, especially curated for outpatient procedures, thus driving the market growth.
Product (Venous Closure Devices, Laser Systems, Surgical Staplers)
Based on product, the venous closure devices segment is expected to hold the second-highest share of 28.8% in the varicose veins treatment market by the end of 2037. The existence and accessibility of venous closure devices such as Medtronic’s VenaSeal is poised to generate USD 4.5 billion by the end of the forecast period, which is further fueled by 45.8% of the U.S. Medicare coverage expansion, as stated in the 2025 CMS report. Besides, the biodegradable adhesive sub-segment is also projected to experience extension with a growth rate of 12.6% through approvals received from EU MDR. Also, there is a chance that surgical staples will undergo a 3.4% reduction amid ASC preference for non-invasive treatment options.
End User (Ambulatory Surgical Centers (ASCs), Hospitals, Specialty Clinics)
Based on end user, the ambulatory surgical centers (ASCs) segment is estimated to account for a share of 23.8% in the varicose veins treatment market during the forecast timeline. This segment has the capability to provide care to almost 8.8 million patients every year by the end of 2037, thereby saving almost USD 1,250 per procedure in hospitals, as stated in the 2025 AHRQ report. Besides this, the segment is expected to grab 65.5% of varicose vein treatment procedures for Germany’s outpatient policy mandates by 2030. Therefore, with this facility, hospitals will be able to retain 30.3% for complicated CVI cases, but will eventually undergo a 17.5% decline in volume yearly.
Our in-depth analysis of the global market includes the following segments:
|
Treatment Type |
|
|
Product |
|
|
End User |
|
|
Disease Stage |
|
|
Sclerotherapy Agent |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportVaricose Veins Treatment Industry - Regional Synopsis
North America Market Analysis
The North America region in the varicose veins treatment market is projected to hold the largest share of 43.8% by the end of 2037. This regional growth is fueled by the presence of both Medicaid and Medicare coverage policies, as well as innovative minimally invasive treatment procedures. The U.S. is projected to account for 89.5% of the overall domestic revenue, with 6.8 million yearly procedures by 2037. On the other hand, Canada’s growth is subjected to expansion in provincial healthcare, with Ontario covering 85.6% of sclerotherapy costs. Therefore, all these factors are highly responsible for driving the market in the region.
The market in the U.S. is undergoing accelerated upliftment due to factors such as increasing insurance coverage and regulatory acceptance of cutting-edge devices. For instance, the U.S. FDA approved 14 latest varicose vein treatment devices in 2024, which included three artificial-intelligence-based diagnostic tools. Besides, in 2025, Medicare’s Physician Fee Schedule enhanced the reimbursement policy by 8.5% for endovenous ablation, which is poised to surge by 23.6% in terms of ASC-based procedures, thereby providing a suitable upliftment for the market in the country.
The varicose veins treatment market in Canada is gaining increased traction owing to cost-effectiveness for outpatient care based on single-payer system, comprising 7 provinces that cover ultrasound-guided sclerotherapy. According to the 2024 BC MOH report, British Columbia’s 2024 Surgical Renewal Plan provided a fund of USD 190 million to keep a check on the varicose vein treatment waitlists, which further reduced average delays from 20 to 10 months. Besides, device procurement remains a barrier, wherein 29% of hospitals report over seven months delay, especially for imported laser fibers, which ultimately prompts the latest federal tax credits for regional medtech manufacturing facilities.
Europe Regional Market Size & Growth
The Europe region in the varicose veins treatment market is projected to account for the second-highest share of 28.9% during the forecast timeline. This growth is highly driven by the rising aging population and the presence of universal healthcare and medical coverage policies. The country has regulatory bodies to approve the latest devices for undergoing treatment procedures. For instance, in 2024, the EU Medical Device Regulation (MDR) enhanced the adoption of non-thermal ablation devices, which currently covers almost 75.5% of overall treatment and diagnostic procedures, thus suitable for uplifting the market in the region.
The varicose veins treatment market in Germany is significantly growing, attributed to the availability of a compulsory health insurance system covering almost 92.5% of minimally invasive procedures. However, stringent price control caps the reimbursement policy at €1,200.5 per procedure, which eventually squeezes margins up to 11% to 16% for device manufacturers. Besides, the regional production facility is responsible for combating costs with 46% of laser devices manufactured by local organizations such as Biolitec AG, thereby amplifying the market expansion in the country.
The market growth in France is propelled by the presence of HAS policies that are considered mandatory for 81% of procedures, especially in an outpatient environment. Moreover, the regional government allocated an investment of €1.2 billion, which is 7.4% of the overall health budget, to ensure varicose veins treatment in 2025. This resulted in prioritizing similar day discharge protocols that diminished hospital accommodation by 30.8%. In addition, tele-rehabilitation programs reduced re-admissions by almost 18.7%, which also contributed to the market expansion in the country.
Competitive Landscape & Strategic Initiatives
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The global varicose veins treatment market comprises key organizations, focusing on strategic initiatives to enhance their market presence across nations. These initiatives include product innovation, strategic mergers and acquisitions, service expansion, partnerships, and collaborations. For instance, in 2023, Boston Scientific acquired BTG at a worth of USD 1.3 billion with the ultimate objective to make expansion of its sclerotherapy portfolio, which denotes a remarkable contribution in the market. In addition, the involvement of government regulations in approving products and services also plays a vital role in making them readily available in the market.
Here is a list of key players operating in the global market:
|
Company Name |
Country of Origin |
Market Share (2024) |
Notable Products |
|
Medtronic |
U.S. |
22.1% |
Market leader in venous closure systems (VenaSeal, ClosureFast) |
|
Boston Scientific |
U.S. |
18.1% |
Radiofrequency ablation devices (ClosureFAST), laser systems |
|
Biolitec AG |
Germany |
12.4% |
ELVeS radial laser fibers, minimally invasive solutions |
|
Teleflex |
U.S. |
11.1% |
ADH enzyme replacement therapies |
|
AngioDynamics |
U.S. |
8.5% |
ADH inhibitors for liver damage |
|
Lumenis |
Israel |
xx% |
ADH biosimilars for metabolic disorders |
|
BTG |
UK |
xx% |
ADH-based biologics for metabolic disorders |
|
Eufoton |
Italy |
xx% |
Generic ADH enzyme therapies |
|
Syneron Medical |
Israel |
xx% |
Monoclonal antibodies for ADH-related conditions |
|
Dornier MedTech |
Germany |
xx% |
Dornier MedTech (Germany) |
Below are the areas covered for each company under the top 15 global manufacturers:
In the News
- In January 2024, VVT Medical and Methapharm partnered with each other to provide a noteworthy evolution within the varicose vein treatment industry, by ensuring synergies between both entities to endorse VVT Medical's ScleroSafe platform throughout the U.S.
- In December 2021, Becton, Dickinson, and Company (BD) successfully acquired Venclose Inc. to expand its business for providing chronic venous insufficiency treatment services, which eventually aimed to expand BD's portfolio in the varicose veins treatment market.
Author Credits: Radhika Pawar
- Report ID: 4936
- Published Date: May 20, 2025
- Report Format: PDF, PPT
